Cyclacel announces dosing of first patient in phase 1/2 study of oral cyc140 in patients with advanced solid tumors and lymphomas

- cyc140, a potent and selective plk1 inhibitor to be evaluated as a single agent across multiple solid tumor and lymphoma types in streamlined, registration-directed study - - cyc140, a potent and selective plk1 inhibitor to be evaluated as a single agent across multiple solid tumor and lymphoma types in streamlined, registration-directed study -
CYCC Ratings Summary
CYCC Quant Ranking